As discussed in our last quarterly, Sirtex Medical reported on 17 March its preliminary SIRFLOX study results in the first-line treatment of non-resectable metastatic colorectal cancer (mCRC). SIRFLOX was the first large Randomised Control Trial (RCT) of a liver-directed therapy. The limited headline data released in the announcement caught the market by surprise as the stock traded near its all-time high.
As way of background, the primary endpoint of the SIRFLOX trial aimed to show a statistically significant improvement in overall Progression-Free Survival (PFS) in all sites of the body, including those outside the liver. On this point, the results were shown not to be statistically significant, however, this controversial primary endpoint was not the only key scientific finding from the trial.
Sirtex provided a second release to the market in mid-May that gave new clarity for a subset of patients with metastatic colorectal cancer, a cancerous tumour that has spread from the colon to the liver. This secondary endpoint was a critical finding as it showed that the SIR-Spheres Y-90 resin microspheres did result in a statistically significant improvement in median PFS in the liver. Since SIR-Spheres are specifically targeted at liver tumours, this treatment importantly offers new hope for beating a disease where the dominant cause of death are liver metastasis.
In our June quarterly we provide a more detailed discussion of our findings from the American Society of Clinical Oncology’s Annual General Meeting in Chicago where Sirtex Medical presented the headline results of the SIRFLOX trial. The following video of Dr. Dirk Arnold’s interpretation is worthy of sharing.
Source: OncLive TV, Youtube